CA2436083A1 - Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders - Google Patents

Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders Download PDF

Info

Publication number
CA2436083A1
CA2436083A1 CA002436083A CA2436083A CA2436083A1 CA 2436083 A1 CA2436083 A1 CA 2436083A1 CA 002436083 A CA002436083 A CA 002436083A CA 2436083 A CA2436083 A CA 2436083A CA 2436083 A1 CA2436083 A1 CA 2436083A1
Authority
CA
Canada
Prior art keywords
alkyl
antagonist
group
histamine
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002436083A
Other languages
English (en)
French (fr)
Inventor
John A. Hey
Robert G. Aslanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2436083A1 publication Critical patent/CA2436083A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002436083A 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders Abandoned CA2436083A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26735201P 2001-02-08 2001-02-08
US60/267,352 2001-02-08
PCT/US2002/003975 WO2002072093A2 (en) 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders

Publications (1)

Publication Number Publication Date
CA2436083A1 true CA2436083A1 (en) 2002-09-19

Family

ID=23018432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002436083A Abandoned CA2436083A1 (en) 2001-02-08 2002-02-06 Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders

Country Status (6)

Country Link
US (1) US6906081B2 (enExample)
EP (1) EP1408965A2 (enExample)
JP (1) JP2004529117A (enExample)
AU (1) AU2002253929A1 (enExample)
CA (1) CA2436083A1 (enExample)
WO (1) WO2002072093A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849621B2 (en) 2001-03-13 2005-02-01 Schering Corporation Piperidine compounds
EP1777223A1 (en) * 2002-06-24 2007-04-25 Schering Corporation Indole derivatives useful as histamine H3 antagonists
US20050090527A1 (en) * 2003-01-28 2005-04-28 Schering Corporation Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
EP1646620B1 (en) * 2003-07-18 2007-08-15 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
EP2813225B1 (en) * 2004-09-24 2017-12-13 University of Maryland, Baltimore Method of treating organophosphorous poisoning
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
US8541452B2 (en) * 2005-10-06 2013-09-24 Guy Chouinard Method for treating binge-eating disorder
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
RU2486187C2 (ru) 2007-09-11 2013-06-27 Эбботт Лэборетриз N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА
MX344177B (es) * 2008-03-27 2016-12-08 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
HK1210947A1 (en) 2012-09-05 2016-05-13 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
EP4251148A1 (en) * 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624734A (en) * 1950-04-29 1953-01-06 Hoffmann La Roche Bipiperidine derivatives
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
ZA929788B (en) 1991-12-18 1993-06-22 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring.
US5633250A (en) 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
US5807872A (en) 1992-12-16 1998-09-15 Schering Corporation Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5446057A (en) 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
HUT74386A (en) 1993-11-15 1996-12-30 Schering Corp Phenyl-alkyl imidazoles as h3-receptor antagonists and pharmaceutical compositions containing them
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5935958A (en) 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US5977138A (en) 1996-08-15 1999-11-02 Schering Corporation Ether muscarinic antagonists
US6034251A (en) 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
US5990147A (en) 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6066636A (en) 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
US6100279A (en) 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US6294554B1 (en) 1999-09-22 2001-09-25 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
EP1408965A2 (en) 2004-04-21
WO2002072093A2 (en) 2002-09-19
JP2004529117A (ja) 2004-09-24
US6906081B2 (en) 2005-06-14
WO2002072093A3 (en) 2004-01-22
US20020151565A1 (en) 2002-10-17
AU2002253929A1 (en) 2002-09-24

Similar Documents

Publication Publication Date Title
US10881648B2 (en) Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
AU730856B2 (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
JP5885359B2 (ja) Ａｔｐ結合カセットトランスポーターのイソキノリン調節因子
CA2436083A1 (en) Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
EP2140865A1 (en) Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
EA006604B1 (ru) Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
BG63678B1 (bg) Трихидрат на (1s,2s)-1-(4-хидроксифенил)-2-(4-хидрокси- 4-фенилпиперидин-1-ил)-1-пропанол метансулфонат
WO2019157505A1 (en) A method of treating pain
KR20140078742A (ko) 탈유비퀴틴화 활성의 저해 방법
PH26920A (en) Medicaments for the treatment of cerebral apoplexy
EP3823627A1 (en) Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
NL1028193C2 (nl) Farmaceutisch werkzame verbindingen.
AU2007272720A1 (en) Methods for treating cystic kidney diseases
JP5467044B2 (ja) Ｔｓｈ受容体拮抗性のテトラヒドロキノリン化合物
CA2557650A1 (en) Ion channel modulators
JP4098523B2 (ja) Ｃｎｓ障害に対するカルボニルアミノ誘導体の使用
EP3915978A1 (en) N-benzyl-n-arylsulfonamide derivative and preparation and use thereof
RU94043786A (ru) Замещенные фенилкарбаматы и фенилмочевины, способ их получения и их применение в качестве 5-нт-антагонистов
CN107404876B (zh) 抗癌治疗剂
CA2466728C (en) Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
EP2454240A1 (en) Glycine transporter inhibitors
EP4079730A1 (en) Novel deuterium-substituted pyrimidine derivative and pharmaceutical composition comprising same
CA2248134A1 (en) Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers
US4382935A (en) Analgesic drug containing a derivative of benzylpiperazine

Legal Events

Date Code Title Description
FZDE Discontinued